Back to top
more

bluebird bio (BLUE)

(Real Time Quote from BATS)

$0.50 USD

0.50
1,416,271

+0.01 (1.07%)

Updated Oct 11, 2024 12:16 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (85 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for BLUE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for bluebird bio, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 222 180 300 1,151 1,106
Receivables 22 11 11 0 0
Notes Receivable 0 0 0 0 0
Inventories 23 0 0 0 0
Other Current Assets 15 8 26 64 46
Total Current Assets 282 199 337 1,216 1,152
Net Property & Equipment 66 9 10 163 151
Investments & Advances 0 1 97 123 132
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 16 11 6 23 27
Deposits & Other Assets 54 52 53 73 79
Total Assets 619 555 594 1,781 1,727
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 19 25 26 22 43
Current Portion Long-Term Debt 3 0 0 0 0
Current Portion Capital Leases 85 0 0 0 0
Accrued Expenses 73 52 104 145 142
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 0 0 0 12 19
Total Current Liabilities 200 128 153 204 224
Mortgages 0 0 0 0 0
Deferred Taxes/Income 0 0 0 26 10
Convertible Debt 0 0 0 0 0
Long-Term Debt 38 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 29 38
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 425 359 220 426 442
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 2 1 1 1 1
Capital Surplus 4,455 4,186 4,096 4,260 3,568
Retained Earnings -4,260 -3,987 -3,720 -2,901 -2,282
Other Equity -2 -4 -3 -6 -2
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 195 196 374 1,355 1,285
Total Liabilities & Shareholder's Equity 619 555 594 1,781 1,727
Total Common Equity 195 196 374 1,355 1,285
Shares Outstanding 109.30 82.90 70.10 66.30 55.30
Book Value Per Share 1.78 2.37 5.34 20.44 23.24

Fiscal Year End for bluebird bio, Inc falls in the month of December.

All items in Millions except Per Share data.

9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Assets          
Cash & Equivalents -99,999 144 212 222 174
Receivables NA 1 1 22 23
Notes Receivable NA 0 0 0 0
Inventories NA 33 30 23 21
Other Current Assets NA 25 28 15 29
Total Current Assets NA 204 272 282 247
Net Property & Equipment NA 79 90 66 10
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 16 16 16 11
Deposits & Other Assets NA 58 58 54 51
Total Assets NA 545 631 619 614
Liabilities & Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 31 19 19 20
Current Portion Long-Term Debt NA 75 72 3 0
Current Portion Capital Leases NA 101 114 85 0
Accrued Expenses NA 66 64 73 58
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 0 0 0 10
Total Current Liabilities NA 298 294 200 159
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 0 0 0 0
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 20 26 38 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 492 500 425 391
Shareholders Equity 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 2 2 2 1
Capital Surplus NA 4,465 4,461 4,455 4,334
Retained Earnings NA -4,412 -4,330 -4,260 -4,110
Other Equity NA -2 -2 -2 -2
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 53 131 195 223
Total Liabilities & Shareholder's Equity NA 545 631 619 614
Total Common Equity 0 53 131 195 223
Shares Outstanding 193.90 193.50 193.50 109.30 106.90
Book Value Per Share 0.00 0.27 0.68 1.78 2.08